Seattle, WA–(HISPANIC PR WIRE)–June 24, 2004–Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE: SHR, FSE: SCH), today announced the launch of Leukine.com, its newly designed Web site for patients undergoing cancer therapy, their caregivers, and healthcare professionals. The modernized site is now easier to navigate and offers several new user-friendly features, many of which are available to patients and caregivers in both English and Spanish.
The new site represents the first major revision to Leukine.com since Berlex acquired LEUKINE® (sargramostim), a growth factor that helps fight infection and disease in appropriate patients by enhancing cells of the immune system, in July 2002.
“We are very excited about the depth and breadth of the new Leukine.com site,” said Craig Philips, Vice President of Marketing for Berlex Oncology. “Specifically, the addition of new content, available both to Spanish- and English- speaking visitors, will allow patients undergoing cancer therapy to learn about topics of particular importance to them such as the immune system, bone marrow transplantation, and minimizing the risk of infection.”
Additional improvements to the patient portion of the site include informational brochures that can be downloaded in both English and Spanish and new graphic icons. In addition, Leukine.com provides patients with a list of advocacy organizations and Web sites with information about various clinical trial programs.
Upgrades to the Healthcare Professionals’ section include comprehensive product information, interactive tools, key LEUKINE studies and slide kits, reimbursement information and nursing and patient support tools. Leukine.com also offers healthcare professionals an extensive list of additional resources including links to professional online journals and sites offering continuing medical education (CME/CE) credits.
“The new Leukine.com offers an array of new and improved features, as well as up-to-date oncology information,” said Carol Pohlod, Senior Product Manager for LEUKINE. “In the past, we have received numerous requests from doctors and nurses looking for information about LEUKINE and its role in oncology. Obtaining that specific information is now as easy as visiting our all-new Web site.”
Leukine.com also offers visitors the opportunity to download the latest 2004 desktop calendar wallpaper each month, featuring images by nature photographer Bruce W. Heinemann. The calendar can be found in the Healthcare Professionals section under the Additional Resources link.
To learn more about LEUKINE, please visit http://www.Leukine.com.
LEUKINE is a growth factor that stimulates neutrophils, monocytes/macrophages, and dendritic cells, and is marketed by Berlex, Inc.
LEUKINE is the only growth factor approved in the U.S. for use following induction chemotherapy in older adults with acute myelogenous leukemia (AML) to shorten the time to neutrophil recovery and reduce the incidence of severe and life-threatening infections and infections resulting in death. LEUKINE has also been approved in the U.S. for use in four additional indications: myeloid reconstitution following allogeneic and autologous bone marrow transplantation (BMT), peripheral blood stem cell (PBSC) mobilization and subsequent myeloid reconstitution in patients undergoing PBSC transplantation, and bone marrow transplantation failure or engraftment delay.
Patients taking LEUKINE may experience some side effects, most of which are mild to moderate. Some common side effects may include bone pain, a slight temperature elevation (usually less than 100.5º F or 38ºC) for a short period of time after the injection, and swelling, redness, and/or discomfort around the injection site.
For full prescribing information, please visit http://www.Leukine.com.
Committed to developing novel diagnostics and therapeutics that address unmet medical needs, Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE: SHR), develops and markets diagnostic imaging agents, treatments in the areas of female healthcare and dermatology, as well as specialized therapeutics for life-threatening and disabling diseases in the fields of the central nervous and cardiovascular systems, oncology, and gastroenterology. Berlex has business operations in New Jersey, California and Washington. For more information, please visit http://www.berlex.com.